PC
BHVN icon

Pier Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Pier Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36,491
Closed -$4.33M – 112
2022
Q1 		$4.33M Sell
36,491
-49,411
-58% -$6.16M 0.55% 85
2021
Q4 		$11.8M Sell
85,902
-1,311
-2% -$167K 1.25% 27
2021
Q3 		$12.1M Sell
87,213
-26,705
-23% -$3.33M 1.26% 22
2021
Q2 		$11.1M Sell
113,918
-49,016
-30% -$3.98M 1.11% 41
2021
Q1 		$11.1M Buy
162,934
+96,322
+145% +$7.79M 1.06% 54
2020
Q4 		$5.71M Buy
66,612
+2,117
+3% +$179K 0.6% 90
2020
Q3 		$4.19M Sell
64,495
-813
-1% -$53.3K 0.61% 91
2020
Q2 		$4.78M Sell
65,308
-36,726
-36% -$1.95M 0.76% 80
2020
Q1 		$3.47M Buy
102,034
+35,135
+53% +$1.61M 0.77% 68
2019
Q4 		$3.64M Sell
66,899
-42,026
-39% -$2.08M 0.6% 87
2019
Q3 		$4.54M Sell
108,925
-4,650
-4% -$196K 0.77% 74
2019
Q2 		$4.97M Buy
113,575
+44,786
+65% +$2.52M 0.77% 78
2019
Q1 		$3.54M Buy
+68,789
New +$2.97M 0.55% 92

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pier Capital's BHVN Position: Q2 2022 in Review

Pier Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 36,491 shares — an estimated $4.33M sold.

Pier Capital first reported a position in BHVN in Q1 2019 and held it in 13 quarters. The position peaked at $12.1M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Pier Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Pier Capital sold 36,491 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $4.33M.
  • Pier Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 13 quarters.
  • Pier Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.1M in Q3 2021.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Pier Capital's 13F filing for Q2 2022, filed 15 Aug 2022.